Arcutis Biotherapeutics, Inc


HBM contact: Dr Alexander Asam, Dr Emil Bujak

Company status: private

Arcutis Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The lead asset "ARQ-151" is under development for topical treatment in Plaque Psoriasis and has shown positive results in a clinical phase 2b study.  "ARQ-151“ will commence clinical Phase 3 studies in 2020. In addition, Arcutis has various other ongoing development projects.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171